Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Yoshifumi Wada"'
Autor:
Yuka Kurokawa, Yusuke Kaida, Takuma Hazama, Yosuke Nakayama, Takaomi Otome, Ryo Shibata, Sakuya Ito, Goh Kodama, Nao Nakamura, Takatoshi Kambe, Tomofumi Moriyama, Akiko Nagata, Aki Minami, Ryotaro Ando, Yoshifumi Wada, Miki Sugiyama, Michiaki Usui, Michio Chiba, Atsuo Moriyama, Atsuko Ohara, Hiroshi Miyazaki, Tatsuyuki Kakuma, Kei Fukami
Publikováno v:
Renal Replacement Therapy, Vol 6, Iss 1, Pp 1-10 (2020)
Abstract Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalc
Externí odkaz:
https://doaj.org/article/44fc4637fec249aab21820b2c2f391c2
Autor:
Aki Minami, Takuma Hazama, Tatsuyuki Kakuma, Akiko Nagata, Kei Fukami, Ryo Shibata, Miki Sugiyama, Yoshifumi Wada, Nao Nakamura, Yusuke Kaida, Ryotaro Ando, Michio Chiba, Sakuya Ito, Atsuko Ohara, Atsuo Moriyama, Michiaki Usui, Yosuke Nakayama, Tomofumi Moriyama, Goh Kodama, Takaomi Otome, Yuka Kurokawa, Hiroshi Miyazaki, Takatoshi Kambe
Publikováno v:
Renal Replacement Therapy, Vol 6, Iss 1, Pp 1-10 (2020)
Background Etelcalcetide is the first intravenously administered calcimimetic agent used to manage secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. We evaluated the safety and efficacy of replacing cinacalcet with etelcalcetide in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f0375ca161c9872b89b845383b2e102
https://doaj.org/article/44fc4637fec249aab21820b2c2f391c2
https://doaj.org/article/44fc4637fec249aab21820b2c2f391c2
Publikováno v:
Sustainability
Volume 15
Issue 3
Pages: 2722
Volume 15
Issue 3
Pages: 2722
In many countries, 40–60% of the traffic accidents occur at junctions, making the reduction of junction accidents paramount to achieving UN Sustainable Development Goals. In Japan, the road safety guidelines specify the proximity between junctions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ad36a3b6e4d79f4a37b555a6e22aa71
https://doi.org/10.3390/su15032722
https://doi.org/10.3390/su15032722
Publikováno v:
Reports of the City Planning Institute of Japan. 18:185-188
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d5a2d5e9ff6c0777731d3be8efdb24a
https://doi.org/10.11361/reportscpij.18.2_185
https://doi.org/10.11361/reportscpij.18.2_185
Autor:
Makoto Nasu, Yoshifumi Wada, Ryo Shibata, Yuka Kurokawa, Yusuke Kaida, Tomofumi Moriyama, Takuma Hazama, Kyoko Tashiro, Yukie Kinoshita, Yoshihiko Otsubo, Junko Yano, Kei Fukami, Goh Kodama, Kaoru Nakano, Takuya Ariyoshi, Ryuji Iwatani, Kengo Urae, Miki Sugiyama
Publikováno v:
Nutrients
Volume 13
Issue 6
Nutrients, Vol 13, Iss 1900, p 1900 (2021)
Volume 13
Issue 6
Nutrients, Vol 13, Iss 1900, p 1900 (2021)
L-carnitine (LC) supplementation improves cardiac function in hemodialysis (HD) patients. However, whether reducing LC supplementation affects carnitine kinetics and cardiac function in HD patients treated with LC remains unclear. Fifty-nine HD patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7366a3a84b73df9ec0e8ce5abd2ac1a5
https://doi.org/10.3390/nu13061900
https://doi.org/10.3390/nu13061900
Autor:
Yusuke Kaida, Seiya Okuda, Yosuke Nakayama, Nana Obara, Ryotaro Ando, Yoshifumi Wada, Seiji Ueda, Kei Fukami, Kazuko Sakai, Sho-ichi Yamagishi, Aki Minami
Publikováno v:
The Aging Male. 17:238-242
Late-onset hypogonadism (LOH) and depression contribute to cardiovascular disease (CVD) in male hemodialysis (HD) patients. Carnitine deficiency is frequently observed in HD patients, playing a role in CVD. We examined whether carnitine deficiency wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532c36e5e21850801c785cb840bb94af
https://doi.org/10.3109/13685538.2014.888053
https://doi.org/10.3109/13685538.2014.888053
Autor:
Takeki Adachi, Yusuke Kaida, Yoshifumi Wada, Rie Manabe, Sho-ichi Yamagishi, Kei Fukami, Yosuke Nakayama, Ryotaro Ando, Keisuke Kohno, Kazuko Sakai, Seiya Okuda, Takuma Hazama, Seiji Ueda, Takuo Kusumoto
Publikováno v:
Therapeutic Apheresis and Dialysis. 17:35-40
Phosphate binders are useful for the treatment of hyperphosphatemia in hemodialysis (HD) patients. This study was performed to examine the effects of switching from calcium carbonate (CC) to lanthanum carbonate (LC) on bone mineral metabolism and inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7503a565d01972c7ed8a056cb0b7726d
https://doi.org/10.1111/1744-9987.12037
https://doi.org/10.1111/1744-9987.12037
Autor:
Taishi Takenobu, Takashi Takeda, Masaya Mitsuishi, Tomoyuki Akutagawa, Hayato Anetai, Yoshifumi Wada, Shunsuke Yamamoto, Norihisa Hoshino
Publikováno v:
The journal of physical chemistry letters. 6(10)
Organic materials with diverse molecular designs show multifunctional properties such as coupled ferroelectric, optical, ferromagnetic, and transport properties. We report the design of an alkylamide-substituted pyrene derivative displaying fluoresce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69de2a76ae2e2ec003666b917759f345
https://pubmed.ncbi.nlm.nih.gov/26263253
https://pubmed.ncbi.nlm.nih.gov/26263253
Autor:
Kazuko Sakai, Hiroshi Yamazaki, Masayoshi Takeuchi, Yoshifumi Wada, Seiya Okuda, Yusuke Kaida, Miyuki Yokoro, Seiji Ueda, Kei Fukami, Sho-ichi Yamagishi, Makiko Shimizu
Publikováno v:
Journal of cardiovascular pharmacology. 65(3)
Food or supplement-derived L-carnitine is changed to trimethylamine (TMA) by interstinal microbiota, which is further metabolized to trimethylamine-N-oxide (TMAO), being involved in the promotion of atherosclerosis in animal models. Meanwhile, carnit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4123a0c8147d0718e375fbcb8bb198c8
https://pubmed.ncbi.nlm.nih.gov/25636076
https://pubmed.ncbi.nlm.nih.gov/25636076
Publikováno v:
American Journal of Hypertension. 12:980-987
Hypertension is a major complication of recombinant human erythropoietin therapy in patients with end-stage renal disease. Although the mechanisms for this pressor effect remain unknown, in vitro and ex vivo experiments suggest that erythropoietin st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14068dd5c43c22eb739d011be1953c55
https://doi.org/10.1016/s0895-7061(99)00081-3
https://doi.org/10.1016/s0895-7061(99)00081-3